The Transparency Law Nobody Enforces
On March 30, 2026, the Food and Drug Administration sent polite reminder messages to more than 2,200 medical product companies and researchers about clinical trial results they were legally required to publish but never did, the FDA announced April 13. The messages covered more than 3,000 registered trials, nearly 30% of all studies that should have reported outcomes to the public database ClinicalTrials.gov within one year of completion.
Nineteen years after Congress passed the FDA Amendments Act of 2007 mandating trial transparency, the agency is still asking nicely. The March messages sought "voluntary compliance" before the FDA would consider further regulatory action, according to the agency's April 13 announcement, the same approach that has allowed roughly one-third of required trial data to vanish into corporate filing cabinets for nearly two decades.
How Publication Disappears
The 2007 law established clear requirements: sponsors of interventional studies involving FDA-regulated drugs, devices, or biologics must submit results to ClinicalTrials.gov within one year of trial completion. The regulation at 42 C.F.R. Part 11 specifies exactly what companies must report, tabular summaries of participant flow, demographic data, primary and secondary outcomes, statistical test results, and adverse events.
Phase 1 drug trials and device feasibility studies are excluded from the mandate, meaning the 29.6% gap represents trials that clearly fall under reporting requirements, according to FDA data. No ambiguity, no gray area. Companies either submitted the data or they didn't.
The FDA's internal analysis found that recipients of the March 30 messages fell into two categories: those who submitted nothing at all, and those who submitted incomplete information that failed the National Library of Medicine's quality control review process. Some of the 3,000 registered trials were publicly funded, the agency noted, meaning taxpayers paid for research that companies then withheld from doctors and patients who needed it.
The Scale of Missing Information
To understand what 3,000 hidden trials means in human terms, consider that each trial typically enrolls between dozens and thousands of participants. Even conservatively estimating 100 participants per trial, the missing data represents information from approximately 300,000 people who volunteered for medical research, their experiences, outcomes, and adverse events locked away from the doctors and patients who could learn from them.
These aren't abstract statistics. Every one of those 3,000 trials tested a specific medical intervention on real patients. When a trial shows a drug causes serious side effects or a device fails to work, hiding that information means other patients may receive the same ineffective or harmful treatment. Doctors prescribing medications today may be working from an evidence base missing critical safety signals from hundreds of thousands of trial participants.
The Enforcement Charade
The FDA has authority under the 2007 law to impose civil monetary penalties up to $15,107 per day for noncompliance. The agency can seek criminal and civil action for violations. It can withhold government grant funding. In practice, the FDA sends reminder messages.
Commissioner Marty Makary stated in the April 13 announcement that companies are "suppressing unfavorable clinical trial results", a blunt accusation from the agency's own leadership. Yet the March messages represented the first step in what the FDA calls "risk-based compliance efforts": reminders, followed potentially by Pre-Notices of Noncompliance, then Notices of Noncompliance, then maybe, eventually, actual penalties that almost never materialize.
The pathway from violation to consequence is so long and gentle that 2,200 sponsors felt comfortable ignoring federal law entirely. The system isn't broken, it's designed this way. Companies control the data, face minimal risk from suppression, and know the FDA will exhaust every diplomatic option before wielding any real authority.
The Compounding Distortion
Each hidden negative trial makes published positive results look more convincing. FDA leadership acknowledged in its announcement that nondisclosure of unfavorable or negative trial results "undermines clinical decision-making", bureaucratic language for a straightforward problem. Doctors prescribe medications based on an evidence base systematically stripped of failures.
The agency calls this publication bias: when successes appear in the scientific record while failures disappear, the remaining data creates "a distorted perception of the safety and efficacy of medical products," according to the FDA statement. A drug that failed in three unpublished trials but succeeded in two published ones looks like a winner. Patients enroll in new studies testing hypotheses already disproven in secret. The scientific method requires complete information; companies provide carefully curated highlights.
The 29.6% gap isn't randomly distributed. Companies have no incentive to hide trials showing their products work. The missing data skews negative, results showing treatments failed, devices caused complications, or interventions produced no benefit. That systematic absence corrupts every clinical decision downstream.
Penalties Without Teeth
Noncompliant sponsors may face public identification, increased regulatory scrutiny, and what the FDA describes as potential "collateral exposure in litigation and transactions." These are reputational and business risks, not legal consequences. The $15,107 daily fine exists in theory; in practice, the FDA sends reminders and waits for voluntary compliance.
The March 30 messages asked companies to do what the law required them to do two decades ago. Some of these trials completed in 2008, 2012, 2015, years past their one-year reporting deadline, according to ClinicalTrials.gov records. The FDA's response: a polite note suggesting they might want to consider submitting that legally mandated information when they get a chance.
Companies understand the calculation. The cost of hiding unfavorable data, reminder messages, possible scrutiny, theoretical fines, is lower than the cost of publishing results that might hurt sales, trigger liability, or undermine marketing claims. The FDA has created a system where the rational business decision is noncompliance.
The Real Victims
The 2,200 companies facing no meaningful consequences aren't the story's casualties. Patients are. Every doctor who prescribes based on incomplete evidence, every patient who enrolls in a trial repeating hidden failures, every family making treatment decisions from a systematically distorted scientific record, they pay the price for a transparency law the FDA won't enforce.
When a physician recommends a treatment unaware that unpublished trials showed it ineffective or dangerous, the harm is direct and measurable. When a patient experiences side effects that were documented in hidden trial data but never made it to the medical literature, that's not a regulatory failure, it's a preventable injury enabled by nonenforcement.
The agency knows this. Makary's accusation of suppression and leadership's acknowledgment that nondisclosure undermines clinical decisions, both in the April 13 announcement, show the FDA understands exactly what's happening. The March messages weren't sent because the agency suddenly discovered a problem in 2026. They were sent because after 19 years of gentle requests, nearly one-third of required data still hasn't appeared.
What changes now? The FDA may send Pre-Notices to some portion of the 2,200 violators. Some companies may submit data to avoid further reminders. The vast majority will likely wait to see if the agency ever moves beyond warnings to actual enforcement. Based on two decades of evidence, that's a safe bet.
The fundamental question isn't why companies hide unfavorable results, the incentives are obvious. The question is why the FDA, armed with significant legal authority and clear evidence of widespread violation, continues treating corporate noncompliance as a problem best solved through polite correspondence. Until that answer changes, the 29.6% gap will persist, and the scientific record will remain corrupted by the data nobody can see.